Stocks and Investing
Stocks and Investing
Thu, February 29, 2024
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
[ Thu, Feb 29th 2024
] - WOPRAI
Raghuram Selvaraju Reiterated (ADMA) at Strong Buy and Held Target at $6 on, Feb 29th, 2024
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "ADMA Biologics, Inc." (ADMA) at Strong Buy and Held Target at $6 on, Feb 29th, 2024.
Raghuram has made no other calls on ADMA in the last 4 months.
There is 1 other peer that has a rating on ADMA. Out of the 1 peers that are also analyzing ADMA, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Anthony Petrone of "Mizuho" Maintained at Strong Buy with Increased Target to $9 on, Monday, January 22nd, 2024
Contributing Sources